New drug cocktail aims to tame deadly transplant complication
NCT ID NCT07570745
First seen May 06, 2026 · Last updated May 13, 2026 · Updated 1 time
Summary
This study tests whether adding a new oral drug (ivarmacitinib) to standard medications can prevent acute graft-versus-host disease (GVHD) in 82 adults receiving a stem cell transplant from a female donor who has given birth. GVHD is a serious complication where donor cells attack the patient's body. The approach targets inflammation while aiming to preserve the new immune system's ability to fight infection.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GRAFT-VERSUS-HOST DISEASE(GVHD) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Locations
-
Shanghai General Hospital Affiliated to Shanghai Jiao Tong University
RECRUITINGShanghai, Shanghai Municipality, 210000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.